PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Research & Development: MAD0.0 Mil (TTM As of Dec. 2025)


CAS:PRO PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
84 GF Score
Price MAD1,349.00
GF Value MAD1,327.72
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Research & Development?

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO 84 Research & Development is MAD0.0 Mil as of Dec. 2025. GuruFocus rates CAS:PRO with a GF Score™ of 84/100 and a GF Value™ of MAD1,327.72 (Fairly Valued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Research & Development for the six months ended in Dec. 2025 was MAD0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was MAD0.0 Mil.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM  (CAS:PRO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Research & Development Related Terms

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Research & Development Historical Data

* Premium members only.

The historical data trend for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Research & Development Chart

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CAS:PRO
84GF Score
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MAD0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MAD0.0 Mil mean?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a Research & Development of MAD0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Research & Development too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Research & Development is MAD0.0 Mil. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Research & Development compare to ZTS and UTHR?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Research & Development of MAD0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Research & Development is MAD0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,327.72, compared to a current price of MAD1,349.00 — trading 1.6% above its estimated fair value. The current Research & Development is MAD0.0 Mil. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current Research & Development is MAD0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?

Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued. The current stock price of MAD1,349.00 is trading 1.6% above its estimated GF Value™ of MAD1,327.72. GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.

Key valuation signals for CAS:PRO:

  • Research & Development: MAD0.0 Mil
  • GF Value™: MAD1,327.72 vs. price of MAD1,349.00 (1.6% above fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description

Address Rue N 7, ZI du Sahel, BP 96/97, Berrechid, Had Soualem, MAR, 26400
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
84GF Score

Get the complete analysis for CAS:PRO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MAD1,349.00
Price
MAD1,327.72
GF Value